The earnings call presented a generally positive outlook, highlighting strong revenue growth and significant advancements in the company's pipeline. Although there were some concerns regarding inventory fluctuations and potential regulatory challenges, the company's robust financial position and strategic collaborations suggest continued growth and innovation.

Company Guidance -

Q3 2025

During the Harmony Biosciences second quarter 2025 financial results conference call, the company reported a net revenue of $200.5 million, reflecting a 16% year-over-year increase. The number of average patients using WAKIX, their key product for narcolepsy, grew by approximately 400 during the quarter. The company reaffirmed their full-year revenue guidance of $820 million to $860 million and expressed confidence in achieving over $1 billion in annual revenue from WAKIX alone by the time of its loss of exclusivity in 2030. Harmony is also advancing its pipeline, with a focus on the upcoming Phase III RECONNECT study for ZYN002 in Fragile X syndrome, which has completed enrollment and is expected to deliver top-line data later in the quarter. The company is also working on next-generation formulations of pitolisant, expected to initiate Phase III trials in the fourth quarter of 2025. Harmony's financial performance remains strong, with a non-GAAP adjusted net income of $53.8 million for the quarter and a robust cash position, enabling strategic business development and pipeline expansion opportunities.

Strong Revenue Growth

Harmony Biosciences reported $200.5 million in second quarter net revenue, representing a 16% increase year-over-year, continuing a 4-year streak of profitability.

Pipeline Advancements

The Phase III registrational trial for ZYN002 in Fragile X syndrome completed enrollment, with top-line data expected later this quarter. The company also plans to initiate Phase III trials for pitolisant HD in narcolepsy and idiopathic hypersomnia in Q4 2025.

Expansion and Collaboration

Harmony entered a research collaboration with Circ Biosciences to develop novel regenerative cellular therapies, aligning with their pipeline focus on refractory epilepsy and treatment-resistant narcolepsy.

Financial Strength

Strong cash generation from operations ($79 million) and a cash position of over $670 million provide financial flexibility for strategic business development.

Harmony Biosciences Holdings (HRMY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

HRMY Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 04, 2025	2025 (Q3)	0.74 / -	0.79	―	―	―
Jul 31, 2025	2025 (Q2)	0.70 / 0.68	0.2	240.00% (+0.48)	―	―
May 06, 2025	2025 (Q1)	0.61 / 0.78	0.67	16.42% (+0.11)
Feb 25, 2025	2024 (Q4)	0.73 / 0.85	0.45	88.89% (+0.40)
Oct 29, 2024	2024 (Q3)	0.67 / 0.79	0.63	25.40% (+0.16)
Aug 06, 2024	2024 (Q2)	>-0.01 / 0.20	0.56	-64.29% (-0.36)
Apr 30, 2024	2024 (Q1)	0.60 / 0.67	0.48	39.58% (+0.19)
Feb 22, 2024	2023 (Q4)	0.72 / 0.45	0.79	-43.04% (-0.34)
Oct 31, 2023	2023 (Q3)	0.67 / 0.63	1.44	-56.25% (-0.81)
Aug 01, 2023	2023 (Q2)	0.61 / 0.56	0.39	43.59% (+0.17)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

HRMY Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$35.48	$35.18	-0.85%
May 06, 2025	$29.96	$32.05	+6.98%
Feb 25, 2025	$34.18	$36.97	+8.16%
Oct 29, 2024	$35.75	$41.49	+16.06%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Harmony Biosciences Holdings (HRMY) report earnings?

Harmony Biosciences Holdings (HRMY) is schdueled to report earning on Nov 04, 2025, Before Open (Confirmed).

What is Harmony Biosciences Holdings (HRMY) earnings time?

Harmony Biosciences Holdings (HRMY) earnings time is at Nov 04, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is HRMY EPS forecast?

HRMY EPS forecast for the fiscal quarter 2025 (Q3) is 0.74.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing